Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents.
The MICs of LBM415, a new peptide diformylase inhibitor, were </=0.06 to 4.0 microg/ml for 258 isolates of Staphylococcus aureus and coagulase-negative staphylococci. LBM415 MICs were similar irrespective of whether the strains were methicillin susceptible or resistant. All strains were also susceptible to vancomycin, linezolid, ranbezolid, daptomycin, oritavancin, and quinupristin-dalfopristin. LBM415 at the MIC was bacteriostatic after 24 h.
Credito
Kim
K
Department of Pathology, Hershey Medical Center, P.O. Box 850, Hershey, PA 17033, USA.
Lin
Gengrong
G
Ednie
Lois M
LM
Appelbaum
Peter C
PC
D000581:Amidohydrolases / Q000037:antagonists & inhibitors*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D015169:Colony Count, Microbial; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006801:Humans; D010455:Peptides / Q000494:pharmacology*; D013203:Staphylococcal Infections / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects*; D020713:Vancomycin Resistance
D000900:Anti-Bacterial Agents; D004791:Enzyme Inhibitors; C487638:NVP PDF 713; D010455:Peptides; D000581:Amidohydrolases; C084507:peptide deformylase